Cost Effectiveness Analysis Of Evolocumab, A PCSK9 Inhibitor, From The US Societal Perspective

May 1, 2018, 00:00
10.1016/j.jval.2018.04.368
https://www.valueinhealthjournal.com/article/S1098-3015(18)30668-5/fulltext
Title : Cost Effectiveness Analysis Of Evolocumab, A PCSK9 Inhibitor, From The US Societal Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30668-5&doi=10.1016/j.jval.2018.04.368
First page :
Section Title :
Open access? : No
Section Order : 1221
Categories :
Tags :
Regions :
ViH Article Tags :